Please assess the completion status of the following clinical trial:

Trial Title: Insulin Resistance in Non-alcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Control subjects: nl liver enzymes and no history of liver disease Case subjects: NAFLD on liver biopsy within the past 3 years or presumed NAFLD with otherwise unexplained elevated alanine aminotransferase (ALT) and fatty liver by computerized tomography (CT) scan or ultrasound~* Able to comply with taking 1 pill a day for 6 months and follow-up safety visits~Exclusion Criteria:~* Cases: cirrhosis on liver biopsy or by clinical exam or fibrosis score~* Causes of liver dysfunction other than NASH~* Use of medications associated with hepatic steatosis:~  * glucocorticoids~ * estrogens~ * tamoxifen~ * amiodarone~ * accutane~ * sertraline~* Use of medications that cause insulin resistance:~  * niacin~ * glucocorticoids~ * anti-HIV drugs or atypical antipsychotics~* Use of lipid-lowering medications except stable dose statin~* Use of anti-NASH drugs such as ursodeoxycholic acid, betaine milk thistle~* Use of coumadin~* Use of nitrates~* Significant alcohol consumption: Average \>20 grams/day~* In subjects with diabetes, a hemoglobin A1c (HbA1c) \>7.5% or use of insulin, metformin, rosiglitazone or pioglitazone~* Liver transaminases: ALT \>5x upper limit of normal,~* Iron saturation \>50%~* Creatinine \>1.5 mg/dl for men and \>1.4 mg/dl for women~* Hematocrit \<33%~* Pregnancy or lactation~* Significant weight loss within the past 6 months or since the liver biopsy~* History of significant coronary artery disease or congestive heart failure, retinopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): matching placebo 1 po qd
- Fenofibrate (Type: EXPERIMENTAL): micronized fenofibrate 200 mg 1 po qd
- Pioglitazone (Type: EXPERIMENTAL): pioglitazone 30 mg po qd

Based on this trial design, predict the completion outcome and termination type (if applicable).